11.33

2.16% -0.25

After Hours: 11.33

Phathom Pharmaceuticals Inc (PHAT)

Overview News Price History Option Chain Financials Discussions Forecast

Phathom Pharmaceuticals Inc stock is traded at $11.33, with a volume of 759.66K. It is down -2.16% in the last 24 hours and down -3.41% over the past month. Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Previous Close:

$11.58

Open:

$11.64

24h Volume:

759.66K

Relative Volume:

0.62

Market Cap:

$903.63M

Revenue:

$204.89M

Net Income/Loss:

$-157.30M

P/E Ratio:

-5.3669

EPS:

-2.1111

Net Cash Flow:

$-97.76M

1W Performance:

-4.55%

1M Performance:

-3.41%

6M Performance:

-24.47%

1Y Performance:

+167.85%

1-Day Range:

$11.24

$11.97

1-Week Range:

$11.15

$12.17

52-Week Range:

$3.92

$18.31

Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile

Name

Phathom Pharmaceuticals Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

(877) 742-8466

Address

100 CAMPUS DRIVE,, FLORHAM PARK, NJ

Employee

371

Twitter

Next Earnings Date

2026-04-30

Latest SEC Filings

PHAT's Discussions on Twitter

Compare PHAT vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PHAT Phathom Pharmaceuticals Inc	11.33	923.57M	204.89M	-157.30M	-97.76M	-2.1111
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-27-26	Upgrade	Barclays	Equal Weight → Overweight
Dec-12-25	Initiated	Raymond James	Strong Buy
Dec-09-25	Initiated	Barclays	Equal Weight
Feb-14-25	Initiated	Cantor Fitzgerald	Overweight
May-03-24	Initiated	Stifel	Buy
Jan-05-24	Reiterated	Needham	Buy
Aug-09-23	Initiated	H.C. Wainwright	Buy
May-11-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-13-23	Initiated	Craig Hallum	Buy
Oct-21-22	Initiated	Jefferies	Buy
May-06-22	Downgrade	Evercore ISI	Outperform → In-line
May-12-21	Upgrade	Goldman	Sell → Neutral
Feb-17-21	Initiated	BMO Capital Markets	Outperform
Feb-02-21	Initiated	Guggenheim	Buy
Jun-26-20	Downgrade	Goldman	Neutral → Sell
Nov-20-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Goldman	Neutral
Nov-19-19	Initiated	Jefferies	Buy
Nov-19-19	Initiated	Needham	Buy

View All

Phathom Pharmaceuticals Inc Stock (PHAT) Latest News

May 24, 2026

PHAT SEC FilingsPhathom Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

May 24, 2026

May 22, 2026

Hear Phathom at three upcoming healthcare investor conferences - Stock Titan

May 22, 2026

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times

May 22, 2026

May 21, 2026

Phathom (NASDAQ: PHAT) director gains shares via options and RSUs - Stock Titan

May 21, 2026

Phathom (PHAT) director James Topper receives 24,122 RSUs in equity grant - Stock Titan

May 21, 2026

Director Mark Stenhouse awarded 24,122 RSUs at Phathom (PHAT) - Stock Titan

May 21, 2026

Director at Phathom Pharmaceuticals (PHAT) granted 24,122 RSUs - Stock Titan

May 21, 2026

Director Michael Cola (PHAT) receives 24,122 RSUs in equity award grant - Stock Titan

May 21, 2026

Director Frank Karbe receives 24,122 RSUs at Phathom (NASDAQ: PHAT) under board compensation plan - Stock Titan

May 21, 2026

Director Theodore Schroeder (PHAT) receives 24,122 RSU award under non-employee plan - Stock Titan

May 21, 2026

Phathom Pharmaceuticals (NASDAQ: PHAT) reports 2026 annual meeting vote outcomes - Stock Titan

May 21, 2026

May 20, 2026

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting - The Manila Times

May 20, 2026

Stomach drug vonoprazan draws 28 independent studies at DDW 2026 - Stock Titan

May 20, 2026

May 19, 2026

Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28 - Moomoo

May 19, 2026

Analyst Reiterates Buy on Phathom as Voquezna Strategy Advances; $28 Price Target Maintained - TipRanks

May 19, 2026

May 14, 2026

TradingKey - TradingKey

May 14, 2026

May 12, 2026

Number of shareholders of Phathom Pharmaceuticals, Inc. – NASDAQ:PHAT - TradingView

May 12, 2026

May 09, 2026

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

May 09, 2026

May 05, 2026

Phathom Pharmaceuticals CEO drives new momentum after DDW2026 to advance GI patient care - Traders Union

May 05, 2026

Phathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability Timeline - Yahoo Finance

May 05, 2026

May 04, 2026

Phathom outlines $320M-$345M 2026 revenue as it targets operating profitability by Q3 - MSN

May 04, 2026

May 03, 2026

How Phathom Pharmaceuticals Inc. (PHAT) Affects Rotational Strategy Timing - Stock Traders Daily

May 03, 2026

147,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by Hussman Strategic Advisors Inc. - MarketBeat

May 03, 2026

How The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity Risks - Yahoo Finance

May 03, 2026

May 02, 2026

Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), TELA Bio (TELA) and Nanobiotix (NBTX) - The Globe and Mail

May 02, 2026

May 01, 2026

Phathom Pharmaceuticals Signals Strong Growth on Earnings Call - The Globe and Mail

May 01, 2026

Earnings call transcript: Phathom Pharmaceuticals beats Q1 2026 EPS expectations - Investing.com Australia

May 01, 2026

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 7.5%Should You Buy? - MarketBeat

May 01, 2026

A Quick Look at Today's Ratings for Phathom Pharmaceuticals(PHAT.US), With a Forecast Between $25 to $28 - Moomoo

May 01, 2026

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2026 Earnings Call Transcript - Insider Monkey

May 01, 2026

Phathom Pharmaceuticals announces DDW2026 booth and team participation in Chicago - Traders Union

May 01, 2026

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting - The Manila Times

May 01, 2026

GERD drug VOQUEZNA gets 3 posters and a May 4 presentation at DDW - Stock Titan

May 01, 2026